Jaguar Health (JAGX) Stock Plunges 28% After Historic 1,190% Rally Fades

Key Points

• JAGX shares declined approximately 28% in Wednesday’s premarket session to around $24.82 following Tuesday’s extraordinary 1,190% jump.
• The previous session’s explosive move came after the FDA granted fee waivers for Mytesi and Canalevia-CA1, combined with heavy retail participation.
• The company executed a 1-for-15 reverse stock split in mid-September, resulting in approximately 520,000 shares outstanding.
• While the fee waivers lower regulatory expenses, they do not constitute new drug approvals.
• The company aims to submit a mid-2027 application for crofelemer in treating pediatric MVID.

Shares of Jaguar Health (JAGX) pulled back dramatically in Wednesday’s premarket session, declining roughly 28% to approximately $24.82. This retreat came immediately after Tuesday’s remarkable 1,190% explosion that saw the stock rocket from $2.67 to finish at $34.46.

Jaguar Health, Inc., JAGX

Initial premarket reports indicated JAGX climbing an additional 11%, though this gain subsequently evaporated. The dramatic price swings highlight both the company’s minimal post-reverse-split share float and heightened retail investor enthusiasm.

The biotech firm implemented a 1-for-15 reverse consolidation on September 17 to maintain its Nasdaq listing requirements. According to Securities and Exchange Commission documentation, roughly 520,088 common shares remained in circulation following the split.

FDA Fee Relief Triggered Tuesday’s Explosive Move

The direct catalyst behind the surge came from regulatory developments. The company announced that its Napo Pharmaceuticals subsidiary secured a fiscal year 2027 Prescription Drug User Fee Act exemption for Mytesi, while the FDA’s Center for Veterinary Medicine granted similar relief for Canalevia-CA1.

Mytesi holds existing approval for treating noninfectious diarrhea in HIV/AIDS patients undergoing antiretroviral treatment. Canalevia-CA1 carries conditional approval for managing chemotherapy-induced diarrhea in canines.

These fee exemptions lower the regulatory burden for maintaining the two marketed products. Critically, they differ from new product clearances or positive clinical data announcements.

Future Pak commercializes both therapies in the United States through a licensing agreement. Jaguar retains responsibility for manufacturing and distribution.

Rare Disease Development Drives Long-Term Vision

Jaguar has shifted strategic emphasis toward developing crofelemer for uncommon gastrointestinal conditions. The primary candidate addresses MVID, a severe intestinal condition that can require children to rely on intravenous nutrition indefinitely.

According to company statements, all randomized participants in the MVID trial are advancing into the extension study. Management has disclosed that one patient experienced up to a 48% decrease in intravenous support requirements following prolonged crofelemer administration.

The firm is working toward a mid-2027 new drug application submission for MVID. Simultaneously, it seeks a development and commercialization partnership for this program.

Investors face significant volatility warnings. JAGX remains a micro-cap biotechnology entity with a track record of reverse splits, operating losses and ongoing capital requirements, while Tuesday’s price movement vastly exceeded the financial impact of regulatory fee waivers.

Wednesday’s steep decline underscores these risks. Market participants now weigh the rare disease opportunity against an exceptionally limited float, potential dilution and highly speculative trading patterns.